Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer

ANZ Journal of Surgery

Volumn 75, Issue 1-2, 2005, Pages 10-20

  Blamey, Stephen ^a,c   Barraclough, Bruce ^a   Delbridge, Leigh ^a   Mernagh, Paul ^b   Standfield, Lachlan ^b   Weston, Adele ^b  

^a Department of Health and Ageing ^*  (Australia)

^b M TAG   (Australia)

^c NONE   (Australia)

Author keywords

Cost; Cost analysis; Recombinant protein; Thyroid neoplasm; Thyrotropin

Indexed keywords

RECOMBINANT THYROTROPIN;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; BLEEDING; BONE PAIN; CHILL; CONFUSION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EVIDENCE BASED MEDICINE; FEVER; FOLLOW UP; HEADACHE; HEALTH CARE COST; HEMIPLEGIA; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOTENSION; INSOMNIA; LUNG EMBOLISM; MUSCLE WEAKNESS; NAUSEA; NECK PAIN; NERVOUSNESS; OUTCOMES RESEARCH; PAIN; PARESTHESIA; PATIENT COMPLIANCE; QUALITY OF LIFE; RECURRENT CANCER; RESPIRATORY DISTRESS; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; THIRST; THYROID CANCER; VOMITING;

DECISION SUPPORT TECHNIQUES; HUMANS; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN;

EID: 15444380062     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2005.03281.x     Document Type: Article

References (16)

1. AIHW and AACR. Cancer in Australia 1998. Incidence and mortality data for 1998. Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR) AIHW cat, no. Canberra: AIHW (Cancer Series no. 17), 2001.
2. Cobin RH, Gharib H, Bergman DA et al. AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma 145. Endocr. Pract. 2002; 7: 203-20.
3. Burman KD. How serious are the risks of hormone over-replacement? Thyroid Today 1995; 18: 1-9.
4. HIC. Requested Medicare Items Processed from July 2000 to June 2001. Item Number 61426 [Internet], Australia: Health Insurance Commission (HIC), 2002. [Accessed 15 May 2002.] Available from URL: http://www.hic.gov.au
5. Bandolier. Evidence and diagnostics, Bandolier Extra. Evidence-Based Health Care. Oxford, UK: Xxx, 2002. [Accessed 24 June 2002.] Available from URL: http://www.jr2.ox.ac.uk/bandolier/ Extraforbando/Diagnostic.pdf
6. Robbins RJ, Tuttle RM, Sharaf RN et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 2001; 86: 619-25.
7. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J. Clin. Epidemiol. 1998; 51: 1115-28.
8. Brouwer W, Koopmanschap M. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1988; 13: 563-6.
9. Haugen B, Pacini F, Reiners C et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. 1999; 84: 3877-85.
10. Ladenson P, Braverman L, Mazzaferri E et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. 1997; 337: 888-96.
11. Mazzaferri ELK, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J. Clin. Endocrinol. Metab. 2002; 87: 1490-8.
12. Pacini F, Molinaro E, Lippi F et al. Prediction of disease status by recombinant human TSH-stimulated Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 2001; 86: 5686-90.
13. Meier CA, Braverman LE, Ebner SA et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J. Clin. Endocrinol. Metab. 1994; 78: 188-96.
14. Giovanni V, Arianna L, Antonio C et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: Experience from a large patient cohort in a single centre. Clin. Endocrinol. 2002; 56: 247-52.
15. Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J. Clin. Endocrinol. Metab. 1999; 84: 3867-71.
16. Braga M, Ringel M, Cooper D. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J. Clin. Endocrinol. Metab. 2001; 86: 5148-51.